Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orthofix’ Blackstone Purchase To More Than Double Spinal Sales By 2007

This article was originally published in The Gray Sheet

Executive Summary

Orthofix' acquisition of Blackstone Medical adds spinal implants, including biologics, for marketing alongside the firm's existing noninvasive spinal bone growth stimulators

You may also be interested in...



News In Brief

Syneron buys UltraShape. Smith & Nephew settles foreign bribery charges. Hospitals settle kyphoplasty allegations. More news briefs.

Orthofix Set To Accelerate Advent Cervical Disc Trial Enrollment In Early 2009

Orthofix plans to accelerate a clinical study of its Advent artificial cervical disc in early 2009, the firm said during its first investor day Sept. 8 in New York

Orthofix Set To Accelerate Advent Cervical Disc Trial Enrollment In Early 2009

Orthofix plans to accelerate a clinical study of its Advent artificial cervical disc in early 2009, the firm said during its first investor day Sept. 8 in New York

Related Content

UsernamePublicRestriction

Register

MT023881

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel